Search

Author/Creator Foo, Jason

1. 220 Cost per response for abatacept versus adalimumab in patients with seropositive erosive, early rheumatoid arthritis in the United States, Germany, Spain and Canada. (25th April 2018)

Authors:
Foo, Jason; Rodríguez-Heredia, José M R; Polanco Sánchez, Carlos; Mtibaa, Mondher; Herrmann, Kirsten H; Alemao, Evo; Postema, Roelien; Baerwald, Christoph
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK. (3rd August 2017)

Authors:
Prabhu, Vimalanand; Foo, Jason; Ahir, Harblas; Sarpong, Eric; Merchant, Sanjay
Journal:
Journal of medical economics
Issue:
Volume 20:Number 8(2017)
Page Start:
840
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗